Eli Lilly has responded to criticism of high prices for insulin products in the US by launching a cut-price version of its Humalog brand ... five-pack of injectable pens, says Lilly, which ...

After years of preparation, Eli Lilly is on the ... The Tempo pen is currently compatible with three of Lilly's insulin products, including Humalog and Lyumjev, both insulin lispro-based, and ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50 ...

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50 ...

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50 ...

Eli Lilly is experiencing explosive growth thanks to its diabetes and obesity treatments. Beyond weight loss, the company is quietly building a fast-growing oncology business. This is an enormous ...

Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology. Having examined the options trading patterns of Eli Lilly, our attention now turns directly to the company.

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog ...

In a report released today, Terence Flynn from Morgan Stanley reiterated a Buy rating on Eli Lilly & Co (LLY – Research Report), with a price target of $1,146.00. The company’s shares closed ...

Eli Lilly (NYSE: LLY) has become a beast in healthcare. The excitement surrounding its GLP-1 drugs, Mounjaro and Zepbound, has helped boost its market capitalization to around $650 billion.